5% type I error rate. Baseline characteristics were summarized for each treatment arm. Continuous variables were summarized by mean, standard error, and range. Categorical variables were summarized by frequency and percentage. Continuous variables
Search Results
Brittany Bauman, Rosemarie Mick, Eileen Martinez, Theresa M. Lawless, Lindsey Zinck, Paige Sinclair, Mary Fuhrer, Mark O’Hara, Charles J. Schneider, Peter O’Dwyer, John Plastaras, Ursina Teitelbaum, and Kim A. Reiss
Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza
analyses could be retrieved from only 13 studies. 10 – 12 , 21 – 30 A flow chart indicating the identification of randomized controlled trials for inclusion in the meta-analysis is reported in Figure 1 . Characteristics of Trials Table 1
Walburga Yvonne Joko-Fru, Mirko Griesel, Nikolaus Christian Simon Mezger, Lucia Hämmerl, Tobias Paul Seraphin, Jana Feuchtner, Henry Wabinga, Guy N’da, Assefa Mathewos, Bakarou Kamaté, Judith Nsonde Malanda, Freddy Houéhanou Rodrigue Gnangnon, Gladys Chebet Chesumbai, Anne Korir, Cesaltina Lorenzoni, Annelle Zietsman, Margaret Ziona Borok, Biying Liu, Christoph Thomssen, Paul McGale, Ahmedin Jemal, Donald Maxwell Parkin, and Eva Johanna Kantelhardt
evidence of receiving any CDT For patients with metastatic disease, we described the therapy they received (see Table 1 for therapies). Table 1. Therapy Characteristics for Patients With BC by Stage at Diagnosis Assessing Loss to Follow
Bishal Gyawali, Elvira D’Andrea, Jessica M. Franklin, and Aaron S. Kesselheim
patient and disease characteristics closest to those of the RCT. If a non-RCT contained multiple arms for different doses or different histologies, we chose the dose and tumor cohort with the nearest match to the RCT. If the trial characteristics were
Matthew S. Ning, Prajnan Das, David I. Rosenthal, Bouthaina S. Dabaja, Zhongxing Liao, Joe Y. Chang, Daniel R. Gomez, Ann H. Klopp, G. Brandon Gunn, Pamela K. Allen, Paige L. Nitsch, Rachel B. Natter, Tina M. Briere, Joseph M. Herman, Rebecca Wells, Albert C. Koong, and Mary Frances McAleer
categorical variables. Statistical analyses were performed using SPSS Statistics, version 24 (IBM Corp). For all tests, a P value ≤ .050 was considered statistically significant. Results Patient Characteristics Among 20,534 total RT courses delivered at our
Sapho X. Roodbeen, Marta Penna, Susan van Dieren, Brendan Moran, Paris Tekkis, Pieter J. Tanis, Roel Hompes, and on behalf of the International TaTME Registry Collaborative
procedures, or diagnosis other than adenocarcinoma on final histopathology; and 1,001 were treated in centers where >10% of their cases had ≥1 missing values for the main outcome parameters. Patient and tumor characteristics are outlined in Table 1 . Overall
Danielle S. Graham, Mykola Onyshchenko, Mark A. Eckardt, Benjamin J. DiPardo, Sriram Venigalla, Scott D. Nelson, Bartosz Chmielowski, Arun S. Singh, Jacob E. Shabason, Fritz C. Eilber, and Anusha Kalbasi
regression in each of these subgroup analyses. Statistical analysis was performed using STATA, version 15.1 (StataCorp LLP). Results Characteristics of Study Cohort Overall characteristics of the study cohort are summarized in Table 1 . Most patients were
Vaia Florou, Christopher Nevala-Plagemann, Jonathan Whisenant, Patricia Maeda, Glynn W. Gilcrease, and Ignacio Garrido-Laguna
carcinomas of the breast. They share a lobulated pattern; express MUC1, MUC4, and mammaglobin 1 ; and are stained positive with periodic acid–Schiff and mucicarmine. In addition to morphology, a pathognomonic characteristic of MASC is the presence of the ETV
Stefan W. Krause, Jan Schildmann, Christian Lotze, and Eva C. Winkler
oncology (72%). Many respondents reported having cared for inpatients and outpatients in the previous 6 months. Table 1 summarizes the respondents' characteristics and practice settings. Prevalence, Rationing Strategies, and Rationales for
Sierra Cheng, Matthew C. Cheung, Di Maria Jiang, Erica McDonald, Vanessa S. Arciero, Doreen Anuli Ezeife, Amanda Rahmadian, Alexandra Chambers, Kelley-Anne Sabarre, Ambika Parmar, and Kelvin K.W. Chan
scoring. Of these 127 RCTs, 108 RCTs comprising 116 treatment comparisons reported HR OS and were therefore included in the primary analysis. Key characteristics of the included RCTs are described in Table 1 . Figure 1. Process of screening and scoring
